Asgard Therapeutics announces today that the Eurostars-funded project REPRogramming tumors INTo immune cells - a revolutionary gene therapy to treat cancer (REPRINT) - has officially kicked-off.
Read moreThe world wealthiest look for cellular reprogramming as the key for longevity with limitless funds for research
Read more“A growing interest in the field and even a fear of missing out on a revolutionary approach.”
Read moreAsgard Therapeutics AB announces the completion of a EUR 6 million seed financing round. The financing was co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
Read moreSmiLe Incubator company Asgard Therapeutics collaborates with Lund University and two European contract research organizations in the project REPRogramming tumors INTo immune cells: a revolutionary gene therapy to treat cancer. The three-year proposal was ranked #4 out of 644 European applications for Eurostars Cut off 15, and is thereby securing a grant of 2 million euros.
Read moreThe 2021 Merck EU Advance Biotech Grants Program aims to support emerging biotech companies pushing innovative drugs to the market by allowing grant recipients to receive free products and services.
Read moreAsgard Therapeutics project “Turning head and neck cancer into immune cells: preclinical validation and clinical plan of TrojanDC” in collaboration with Skåne University Hospital and Lund University was awarded with Sweden’s SWElife innovation grant.
Read moreIn a new survey published by Øresund Institute and Medicon Valley Alliance, Asgard Therapeutics was highlighted as one of 426 life science companies in Skåne.
Read more